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lAbstract
The thermal reaction of Ru3(CO)12 with the biologically active acids acetyl salicylic acid (Aspirin), a-methyl-4-(isobutyl)phenylacet
acid (Ibuprofen) and 3a,7a,12a-trihydroxy-5b-cholanic acid (cholic acid) in reﬂuxing tetrahydrofuran, followed by addition of tripheny
phosphine, gives the dinuclear complexes Ru2(CO)4(OOCR)2(PPh3)2 (1: R = C6H4-2-OCOMe, 2: R = CHMe-C6H4-4-Bu
i, 3: C23H39O3
The single-crystal structural analysis of 1 and 2 reveals a dinuclear Ru2(CO)4 sawhorse structure, the diruthenium backbone bein
bridged by the carboxylato ligands, while the two phosphine ligands occupy the axial positions at the ruthenium atoms. However, chira
carbon atoms in the carboxylic acid undergo racemisation during the thermal reaction.
Keywords: Carbonyl ligands; Carboxylato bridges; Biologically active acids; Dinuclear complexes; Rutheniumn
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.1. Introduction
Sawhorse-type ruthenium complexes are well-know
since 1969, when J. Lewis and co-workers reported the
formation by reﬂuxing Ru3(CO)12 in the correspondin
carboxylic acid and the depolymerisation of these materia
in coordinating solvents to give dinuclear complexes of th
type Ru2(CO)4(OOCR)2L2, L being a two-electron dono
[1]. These dinuclear complexes have been shown late
by a single-crystal X-ray structure analysis o
Ru2ðCOÞ4ðOOCBunÞ2ðPBut3Þ2 to have a Ru2(CO)4 back
bone in a sawhorse-type arrangement with two l2-g
2-carb
oxylato bridges and two axial (phosphine) ligands [2]. Sinc
their discovery, a considerable number of such sawhorse
type diruthenium complexes with carboxylato bridges hav
been synthesized and studied [3], used in catalysis [4–6] o
for the assembly of mesomorphic materials [7].
Herein, we present the synthesis and molecular structur
of three new Ru2(CO)4 sawhorse-type complexes contain
ing carboxylato ligands derived from biologically activf
e* Corresponding author.
E-mail address: georg.suess-ﬁnk@unine.ch (G. Su¨ss-Fink).molecules, such as anti-inﬂammatory drugs or steroi
hormones. Acetyl salicylic acid (Aspirin) and a-methyl-4
(isobutyl)phenylacetic acid (Ibuprofen) are used as ant
inﬂammatory pain-killers, the biological function of whic
is to reduce the synthesis of prostaglandins by insertio
into the enzymatic cavity of cyclo-oxygenase [8]. Choli
acid, a steroid hormone, is the most abundant bile aci
in the human body, it plays an important role in fat emu
siﬁcation during the digestion process [8].
2. Results and discussion
Dodecacarbonyltriruthenium reacts with the appropr
ate carboxylic acid in reﬂuxing tetrahydrofuran to give
in the presence of triphenylphosphine, the dinuclear com
plexes Ru2(CO)4(OOCR)2(PPh3)2 in good yields (se
Scheme 1).
Compounds 1, 2 and 3 are air-stable yellow crystallin
powders which have been characterised by their IR
NMR and MS as well as by the micro-analytical data
All compounds 1, 2 and 3 exhibit in the m(CO) region o
the infrared spectrum, the characteristic pattern of th
Ru2(CO)4 sawhorse unit.
2/3 Ru3(CO)12 + 2 RCOOH + 2 PPh3 Ru2(CO)4(OOCR)2(PPh3)2 + 4 CO + 2 H2
Ru Ru
O O O O
C C
C C C C
PPh3Ph3P
R R
O O O O
R 1 3 
 C6H4-2-OCOMe CHMe-C6H4-4-Bui C23H39O3
2
Scheme 1.
2The single-crystal structure analyses of 1 and 2 show the
Ru2(CO)4 sawhorse backbone with the two phosphine
ligands in the axial positions and the carboxylato bridges
in the equatorial positions. The Ru–Ru distances [1:
2.7362(4) A˚, 2: 2.7251(5) A˚] are in the range of a ruthe-
nium–ruthenium single bond, as it was also observed in
analogous complexes [2,3b,3d]. The OCO bond angles of
the carboxylato bridges [1: 125.0(2) and 125.4(2), 2:
125.0(4) and 125.1(3)] diﬀer only slightly from those
observed in other Ru2(CO)4(OOCR)2L2 complexes
[2,3b,3d] (see Fig. 1).
While the aspirin derivative 1 is an achiral molecule, the
ibuprofen derivative 2 containing an asymmetric carbon
atom in both carboxylato ligands is chiral. Surprisingly, a
dichloromethane solution of 2 shows no CD signal,
although 2 had been synthesised with the S enantiomer
of a-methyl-4-(isobutyl)phenylacetic acid (Ibuprofen). This
suggests that racemisation must have occurred during the
synthesis (thermal reaction at 120 C), although the 1H
NMR signals of 2 in CDCl3 do not split into two sets of
signals upon addition of europium(III) tris[3-(trif-
luoromethylhydroxymethylene)-d-camphorate] (chiral shift
reagent), as expected for a racemic mixture. However, the
racemised carboxylato ligands are clearly seen in the molec-
ular structure of 2. Comparative CD spectra of enantio-
pure commercial ibuprofen and of ibuprofen heated to
120 C in thf during 12 h give no further information,
because these compounds have an UV maximum ofRu Ru
O O O O
C C
C C C C
PPh3Ph3P
O O O O
O
O
O
O
1
Fig. 1. Lewis representations of the aspirin and ibuprofen derivatives Ru2(CO
Bui)2(PPh3)2 (2).absorption around 260 nm which is outside the CD limit
detection.
Compound 3, being a steroid hormone derivative, was
synthesised by reacting cholic acid with Ru3(CO)12. The
molecular constitution can be deduced unambiguously
from the spectroscopic data. The CD spectrum of 3 shows
that it is not optically active, although it had been formed
from enantiopure cholic acid. Obviously, cholic acid under-
went racemisation during the synthesis of 3. The racemisa-
tion is a consequence of the thermal treatment during the
reaction. Indeed, comparative CD spectra of the enantio-
pure commercial cholic acid and of cholic acid heated in
thf over 12 h, conﬁrm the racemisation, since the CD signal
disappears completely (see Fig. 3).
In conclusion, we have shown that biologically active
molecules such as anti-inﬂammatory drugs and steroid hor-
mones can be derivatised by their carboxylic acid function
with Ru2(CO)4 sawhorse unit. However, chiral carbon
atoms in the carboxylic acid undergo racemisation during
the thermal process.
3. Experimental
3.1. General
All manipulations were carried out by routine methods
under nitrogen atmosphere. Organic solvents were degassed
and saturated with nitrogen prior to use. All reagents wereRu Ru
O O O O
C C
C C C C
PPh3Ph3P
O O O O
2
)4(OOCC6H4-2-OCOMe)2(PPh3)2 (1) and Ru2(CO)4(OOCCHMe-C6H4-4-
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Fig. 2. Molecular structures of Ru2(CO)4(OOCC6H4-2-OCOMe)2(PPh3)2 (1) and Ru2(CO)4(OOCCHMe-C6H4-4-Bu
i)2(PPh3)2 (2), hydrogen atoms being
omitted for clarity.
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Fig. 3. Lewis representation of the cholic acid derivative Ru2(CO)4(OOC-
C23H39O3)2(PPh3)2 (3).
3purchased either fromAldrich orFluka, and used as received
NMR spectra were recorded on a Bruker 400 MHz spec
trometer. IR spectra were recorded on a Perkin–Elme
1720X FT-IR spectrometer (4000–400 cm1). Microanalyse
were performed by the Laboratory of Pharmaceutical Chem
istry, University of Geneva, Switzerland. Electro-spray mas
spectra were obtained in positive-ion mode with an LCQ
Finnigan mass spectrometer. Dodecacarbonyltriruthenium
[9] was prepared according to published methods.e
-
):
,
,
),
83.2. General method for the preparation of complexes
A solution of Ru3(CO)12 (200 mg, 0.32 mmol) and th
appropriate carboxylic acid (0.94 mmol) in dry tetrahydrofuran (40 ml) was heated at 120 C in a pressure Schlen
tube for 12 h. Then the solvent was evaporated to give
yellow–brown residue, which was dissolved in tetrahydro
furan, and the triphenylphosphine (0.94 mmol) was added
The solution was stirred at room temperature for 2–3 h
evaporated and the product isolated from the residue b
crystallization from a tetrahydrofuran/hexane mixture. I
order to improve the purity, the raw product was subjecte
to a thin-layer chromatography on silica gel using dichloro
methane as eluent and obtained as yellow powder.
Ru2(CO)4(OOCC6H4-2-OCOMe)2(PPh3)2 (1): Yield
77% (290 mg, 0.24 mmol). 1H NMR (400 MHz, CDCl3
d = 7.58–7.53 ppm (m, 12H, Har), 7.46–7.33 (m, 18H
Har), 7.42 (m, 2H, Har), 7.03 (dd, 2H, Har, J = 1.2, 8 Hz
6.91 (td, 2H, Har, J = 1.2, 8 Hz), 6.65 (dd, 2H, Ha
J = 1.7, 8 Hz), 1.60 (s, 6H, CH3);
13C{1H} NMR
(100 MHz, CDCl3): d = 205.68 ppm (4C, CO), 180.7
(2C, COO), 169.50 (2C, COOCH3), 148.74 (2C, Car
134.26 (6C, Car), 134.20 (12C, Car), 131.77 (2C, Car
131.02 (2C, Car), 129.37 (6C, Car), 128.71 (12C, Car
125.40 (2C, Car), 122.24 (2C, Car), 20.43 (2C, CH3
31P{1H} NMR (162 MHz, CDCl3): d = 13.03 ppm; IR
(CaF2, THF): m(CO) 2022 vs, 1978 m, 1920 vs, m(OCO) 156
s cm1; ESI-MS: 1221 [M+Na]+, 959 [MPPh3]+. Ana
Calc. for C58H44O12P2Ru2 (1197.05): C, 58.19; H, 3.70
Found: C, 58.27; H, 3.83%.
Ru2(CO)4(OOCCHMe-C6H4-4-Bu
i)2(PPh3)2 (2): Yield
51% (198 mg, 0.16 mmol). 1H NMR (400 MHz, CDCl3
d = 7.54–7.34 ppm (m, 30H, Har), 6.89 (d, 4H, Ha
J = 8 Hz), 6.75 (d, 4H, Har, J = 8 Hz), 3.27 (q, 2H, CH
J = 7 Hz), 2.44 (d, 4H, CH2, J = 7 Hz), 1.85 (m, 2H
CH), 1.02 (d, 6H, CH3, J = 7 Hz), 0.92 (dd, 12H, CH
J = 1.9, 7 Hz); 13C{1H} NMR (100 MHz, CDCl3
d = 205.70 ppm (4C, CO), 189.84 (2C, COO), 140.03 (6C
Car), 134.24 (12C, Car), 129.97 (6C, Car), 129.16 (4C
Car), 128.59 (12C, Car), 127.58 (4C, Car), 47.93 (2C, CH
45.53 (2C, CH2), 30.67 (2C, CH), 22.90 (4C, CH3), 19.3
4(2C, CH3);
31P{1H} NMR (162 MHz, CDCl3):
d = 14.56 ppm; IR (CaF2, THF): m(CO) 2023 vs, 1980 m,
1953 vs, m(OCO) 1568 s cm
1; ESI-MS: 1273 [M+Na]+,
1250 [M+H]+, 1223 [M4(CO)+2H]+. Anal. Calc. for
C66H64O8P2Ru2 Æ H2O (1267.31): C, 62.55; H, 5.25. Found:
C, 62.22; H, 5.20%.
Ru2(CO)4(OOCC23H39O3)2(PPh3)2 (3): Yield 83%
(430 mg, 0.26 mmol). 1H NMR (400 MHz, CDCl3):
d = 7.56 ppm (m, 12H), 7.43–7.38 (m, 18H), 3.96 (s, 2H),
3.85 (s, 2H), 3.45 (br, 2H), 2.20 (m, 4H), 2.06–0.92 (m,
50H), 0.90 (s, 6H), 0.85 (d, 6H, J = 6.4 Hz), 0.63 (s, 6H);
13C{1H} NMR (100 MHz, CDCl3): d = 205.90 ppm (4C,
CO), 189.38 (2C, COO), 134.27 (12C, Car), 133.76 (6C,
Car), 130.04 (6C, Car), 128.54 (12C, Car), 73.55 (2C, CH),
72.42 (2C, CH), 68.98 (2C, CH), 47.73, 46.77, 41.89,
40.15, 40.08, 36.19, 35.76, 35.48, 35.30, 35.05, 32.90,
30.86, 28.55, 28.11, 26.63, 26.03, 23.60 (34 C, CH and C),
23.00 (2C, CH3), 17.80 (2C, CH3), 12.95 (2C, CH3);
31P{1H} NMR (162 MHz, CDCl3): d = 15.30 ppm; IR
(CaF2, THF): m(CO) 2022 vs, 1978 m, 1920 vs, m(OCO) 1566
s cm1; ESI-MS: 1677 [M+Na]+, 1655 [M+H]+; Anal.
Calc. for C88H108O14P2Ru2 (1653.88): C, 63.91; H, 6.58.
Found: C, 63.51; H, 6.65%.3.3. X-ray crystallography
The single-crystals of 1 and 2 are obtained by slow dif-
fusion of hexane into a chloroform solution of 1 or by slow
diﬀusion of methanol into a dichloromethane solution of 2.
X-ray data for 1; C58H44O12P2Ru2, M = 1197.01
g mol1, monoclinic, P21/n (no. 14), a = 11.604(1),
b = 27.949(1), c = 15.777(1) A˚, b = 91.62(1), U =
5114.6(7) A˚3, T = 173 K, Z = 4, l (Mo Ka) = 0.718 mm1,
9931 reﬂections measured, 6525 unique (Rint = 0.0485)
which were used in all calculations. The ﬁnal wR (F2) was
0.0607 (all data): X-ray data for 2; C66H64O8P2Ru2,
M = 1249.25 g mol1, triclinic, P1 (no. 2), a = 13.339(2),
b = 13.462(2), c = 18.442(2) A˚, a = 76.97(1), b = 75.04(1),
c = 71.67(1), U = 2999.3(6) A˚3, T = 173 K, Z = 2, l (Mo
Ka) = 0.611 mm1, 10927 reﬂections measured, 8809
unique (Rint = 0.0497) which were used in all calculations.
The ﬁnal wR (F2) was 0.1032 (all data). In both, the data
were measured using a Stoe Image Plate Diﬀraction system
equipped with a / circle goniometer, using Mo Ka graphite
monochromated radiation (k = 0.71073 A˚) with / range 0–
200, increment of 1.2, Dmax  Dmin = 12.45–0.81 A˚. The
structure was solved by direct methods using the program
SHELXS-97 [10]. The reﬁnement and all further calculations
were carried out using SHELXL-97 [11]. In 2, the methyl
groups of the asymmetric carbons were treated as disor-
dered with partial occupancy factors of 50:50. In all cases,
the hydrogen atoms were included in calculated positions
and treated as riding atoms using the SHELXL default
parameters. All non-H atoms were reﬁned anisotropically,
using weighted full-matrix least-square on F2. Fig. 2 was
drawn with ORTEP [12].Acknowledgements
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Appendix A. Supplementary data
Full tables of atomic parameters, bond lengths and
angles are deposited at the Cambridge Crystallographic
Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK,
Deposition number: 1 – 293473 and 2 – 293474. Supple-
mentary data associated with this article can be found, in
the online version, at doi:10.1016/j.ica.2006.04.015.References
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